IMPORT-201 (IMP-MEL): A phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist IMM60 and pembrolizumab for advanced melanoma and metastatic non-small cell lung cancer (NSCLC).

Authors

Nicholas Coupe

Oxford University Hospital, Oxford, United Kingdom

Nicholas Coupe , David J. James Pinato , Justin P. Fairchild , Desa Rae Electa Pastore , Steven Innaimo , David Thompson , Uzi Gileadi , Robert A. Kramer , Ian B. Walters , Mark R. Middleton

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

A phase 1 first-in-human dose finding/randomized phase 2 study of IMM60 and pembrolizumab (PEM) in advanced melanoma and non–small cell lung cancer (NSCLC; IMP-MEL).

First Author: Nicholas Coupe

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

A multicenter, phase II study of soluble LAG-3 (Eftilagimod Alpha) in combination with pembrolizumab (TACTI-002) in patients with advanced non-small cell lung cancer (NSCLC) or head and neck squamous cell carcinoma (HNSCC).

First Author: Julio Antonio Peguero

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors.

First Author: Jordi Rodon Ahnert

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Efficacy and safety of capmatinib plus pembrolizumab in treatment (tx)-naïve patients with advanced non–small cell lung cancer (NSCLC) with high tumor PD-L1 expression: Results of a randomized, open-label, multicenter, phase 2 study.

First Author: Tony S. K. Mok